Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

被引：88

作者：

Hochmair, Maximilian J. ^{[1
]}

Morabito, Alessandro ^{[2
]}

Hao, Desiree ^{[3
]}

Yang, Cheng-Ta ^{[4
]}

Soo, Ross A. ^{[5
]}

Yang, James C-H ^{[6
,7
]}

Gucalp, Rasim ^{[8
]}

Halmos, Balazs ^{[8
]}

Wang, Lara ^{[9
]}

Golembesky, Amanda ^{[10
]}

Maerten, Angela ^{[11
]}

Cufer, Tanja ^{[12
]}

机构：

[1] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Dept Resp & Crit Care Med, Sanatoriumstr 2, A-1140 Vienna, Austria

[2] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, I-80131 Naples, Italy

[3] Univ Calgary, Cummings Sch Med, Tom Baker Canc Ctr, Calgary, AB, Canada

[4] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan

[5] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore

[6] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[7] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[8] Montefiore Albert Einstein, Canc Ctr, Dept Oncol, Bronx, NY USA

[9] Boehringer Ingelheim Taiwan Ltd, Clin Trials, Taipei, Taiwan

[10] Boehringer Ingelheim Int GmbH, Epidemiol, Ingelheim, Germany

[11] Boehringer Ingelheim Int GmbH, Med Affairs Oncol, Ingelheim, Germany

[12] Univ Ljubljana, Univ Clin Goln, Med Fac, Ljubljana, Slovenia

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 27期

关键词：

afatinib; osimertinib; NSCLC; sequential; T790M; 1ST-LINE TREATMENT; OPEN-LABEL; T790M MUTATION; SURVIVAL-DATA; ADENOCARCINOMA; GEFITINIB; CHEMOTHERAPY; EFFICACY; TKI;

D O I：

10.2217/fon-2018-0711

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials& methods: In this retrospective, observational, multicenter study, patients (n=204) had T790M-positive disease following first-line afatinib and started osimertinib treatment 10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT03370770

引用

下载

页码：2861 / 2874

页数：14

共 50 条

[31] Data reported for gefitinib use in Caucasian EGFR mutation-positive non-small-cell lung cancer patients
Lake, Francesca
FUTURE ONCOLOGY, 2013, 9 (07) : 930 - 930
[32] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Soejima, Kenzo
Yasuda, Hiroyuki
Hirano, Toshiyuki
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
[33] First- and second-line treatment of non-small-cell lung cancer patients with EGFR mutation-positive tumors
Reck, Martin
Reinmuth, Niels
Heigener, David F.
LUNG CANCER MANAGEMENT, 2012, 1 (03) : 201 - 217
[34] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Khozin, Sean
Weinstock, Chana
Blumenthal, Gideon M.
Cheng, Joyce
He, Kun
Zhuang, Luning
Zhao, Hong
Charlab, Rosane
Fan, Ingrid
Keegan, Patricia
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
[35] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Yoshida, H.
Kim, Y. H.
Ozasa, H.
Nagai, H.
Sakamori, Y.
Tsuji, T.
Nomizo, T.
Funazo, T.
Yasuda, Y.
Hirai, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
[36] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer who have poor performance status
Kimura, Madoka
Nishino, Kazumi
Imamura, Fumio
Nakashima, Kazuhisa
Takahashi, Toshiaki
Sugimoto, Takeya
Akamatsu, Hiroaki
Yamamoto, Nobuyuki
Daga, Haruko
Imai, Hisao
Taira, Tetsuhiko
Miyashita, Yosuke
Ko, Ryo
Hisamatsu, Yasushi
Murakami, Haruyasu
ANNALS OF ONCOLOGY, 2018, 29
[37] A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
Fujimoto, D.
Yokoyama, T.
Yoshioka, H.
Demura, Y.
Hirano, K.
Kawai, T.
Kagami, R.
Ishida, T.
Tomii, K.
Akai, M.
Hirabayashi, M.
Nishimura, T.
Nakahara, Y.
Kim, Y. H.
Yoshimura, K.
Hirai, T.
ANNALS OF ONCOLOGY, 2017, 28
[38] A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
Yokoyama, Toshihide
Yoshioka, Hiroshige
Fujimoto, Daichi
Demura, Yoshiki
Hirano, Katsuya
Kawai, Takahiro
Kagami, Ryogo
Washio, Yasuyoshi
Ishida, Tadashi
Kogo, Mariko
Tomii, Keisuke
Okuno, Takehiro
Akai, Masaya
Hirabayashi, Masataka
Nishimura, Takashi
Nakahara, Yasuharu
Kim, Young Hak
Miyakoshi, Chisato
Yoshimura, Kenichi
Hirai, Toyohiro
LUNG CANCER, 2019, 135 : 175 - 180
[39] BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS
Westerink, L.
Nicolai, J.
Samuelsen, C. H.
Griebsch, I
Postma, M.
VALUE IN HEALTH, 2019, 22 : S472 - S472
[40] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
van Veggel, B.
Santos, J. F. Vilacha Madeira R.
Hashemi, S. M. S.
Paats, M. S.
Monkhorst, K.
Heideman, D. A. M.
Groves, M.
Radonic, T.
Smit, E. F.
Schuuring, E.
van der Wekken, A. J.
de Langen, A. J.
LUNG CANCER, 2020, 141 : 9 - 13

← 1 2 3 4 5 →